Defective Iron Homeostasis in \( \beta 2 \)-Microglobulin Knockout Mice Recapitulates Hereditary Hemochromatosis in Man

By Manuela Santos, Marco W. Schilham, Luke H.P.M. Rademakers, J.J.M. Marx, Maria de Sousa, and Hans Clevers

From the Department of Immunology, Department of Internal Medicine, Eijkman-Winkler Institute and Department of Pathology, University Hospital Utrecht, 3584 CX Utrecht, The Netherlands; and Molecular Pathology and Immunology, Abel Salazar Institute for the Biomedical Sciences, 4400 Porto, Portugal

Summary

Previously, hepatic iron overload resembling that in hereditary hemochromatosis (HH) has been found in \( \beta 2 \)-microglobulin knockout (\( \beta 2 \)-m \(-/-\)) mice. We have now characterized iron metabolism in \( \beta 2 \)-m \(-/-\) mice. The mutant mice fail to limit the transfer of iron from mucosal cells into the plasma. Transferrin saturation is abnormally high. Pathologic iron depositions occur predominantly in liver parenchymal cells. Reconstitution with normal hematopoietic cells redistributes the iron from parenchymal to Kupffer cells, but does not correct the mucosal defect. We conclude that (a) iron metabolism is defective in the gut mucosa as well as the liver of \( \beta 2 \)-m \(-/-\) mice; and (b) a \( \beta 2 \)-m-dependent gene product is involved in iron homeostasis. Recently, a novel gene of the major histocompatibility complex class I family, HLA-H, has been found to be mutated in a large proportion of HH patients. Our data provide functional support for the proposed causative role of HLA-H mutations in HH.

Hereditary hemochromatosis (HH), an autosomal recessive, HLA-linked disease, is one of the most common genetic disorders in man. It is characterized by a failure in regulation of iron absorption, an increase of transferrin saturation, and progressive iron deposition predominantly in the parenchymal cells of several organs (1). Increased iron absorption in HH homozygotes leads to accumulation of iron, with eventual tissue damage and organ dysfunction. When the disorder remains untreated, premature mortality resulting from hepatocellular carcinoma, cirrhosis, cardiomyopathy, or diabetes mellitus is common (2, 3). Removal of iron and the prevention of its reaccumulation by phlebotomy treatment dramatically improves life expectancy in these patients (4–7). The discovery of a tight linkage between HH and the HLA-A locus has led to the clarification of the genetic nature and the autosomal recessive inheritance of the disease (8, 9). A similar disease is not known in animals, and although many attempts have been made to develop an appropriate animal model by dietary application of different iron compounds, severe organ damage as seen in HH could not be reproduced in these models (10).

In a previous study, we have revealed the existence of hepatic iron overload in \( \beta 2 \)-microglobulin (\( \beta 2 \)-m)-deficient mice similar to that found in HH (11, 12). This was based on a histological and quantitative study of the steady-state iron distribution and content in tissues of \( \beta 2 \)-m \(-/-\) mice. These results were confirmed more recently by others (13). In addition, the latter study demonstrated that increased levels of dietary iron led to accelerated iron accumulation, and reported an increased incidence of hepatocellular carcinoma in \( \beta 2 \)-m knockout mice. Such carcinomas are frequently seen in HH patients.

In this report, we characterize the nature of the iron metabolism defect found in \( \beta 2 \)-m \(-/-\) mice. \( \beta 2 \)-m is required for the normal surface expression of classical and nonclassical MHC class I molecules (14, 15). Thus, mice lacking a functional \( \beta 2 \)-m gene fail to express MHC class I products (16, 17). Such mice lack CD8\(^+\) lymphocytes. To analyze a possible involvement of CD8\(^+\) cells, we also analyzed iron metabolism in CD8\(^-\) mice. Mice that are mutant in the TAP-1 peptide transporter do not express classical class I molecules on the surface of their cells (18). Some nonclassical MHC-I molecules can be expressed independently of TAP function, however (19, 20). Therefore, to extend our analysis of the nature of the \( \beta 2 \)-m-dependent molecules involved in iron metabolism, we included the TAP1-/- mice in our study. \( \beta 2 \)-m \(-/-\) mice failed to reduce intestinal iron absorption in the face of iron overload and had abnormally high (>80%) values of transferrin saturation. This defect...
was specific for β2m-/- mice, since the iron status of TAP1-/- mice and CD8-/- mice was comparable to that of controls. Additional results are presented that suggest that the iron metabolism in β2m-/- mice is affected at the level of the gut mucosa, as well as at the level of iron storage in Kupffer cells.

The results presented here reveal a remarkable similarity between iron metabolism in β2m-/- mice and in HH patients, and support the unexpected involvement of MHC class I-like molecule(s) in the regulation of iron homeostasis.

Materials and Methods

Mice. C57BL/6 (B6) female mice aged 6–8 wk were purchased from IFFA Credo (Brussels, Belgium), and used as controls. The β2-microglobulin "knockout" (β2m-/-) mouse (16) were purchased from Jackson Immunoresearch Laboratories (West Grove, PA) and further bred in our animal facility; CD8-/- mice (21) were obtained from Dr. T. Mak (University of Toronto, Toronto, Canada), and further bred in our animal facility. Both mutant mice had been back-crossed onto the C57BL/6 back-ground. Liver samples from TAP-/- mice (18) were obtained from Dr. S. Tonegawa (Massachusetts Institute of Technology, Cambridge). All animals were given a commercial diet (RMH-B®; Hope Farms, Woerden, The Netherlands) or, when indicated, an iron-enriched diet containing 2.5% (wt/wt) carbonyl iron (Sigma Chemical Co., St. Louis, MO) and further bred in our animal facility.

For all animal experiments, written consent was obtained from the local Animal Experiments Committee of Utrecht University (Utrecht, The Netherlands).

Fetal Liver Cell Transfer. Recipient animals were lethally irradiated (9.5 Gy) and reconstituted with 5–10 x 10⁶ day 13 fetal liver cells by intravenous injection. Chimeras were killed at 4, 8, and 12 wk after reconstitution, and chimerism was monitored by FACS® (Becton Dickinson, Mountain View, CA) using CD4, CD8 (PharMingen, San Diego, CA), and H141.31.10 (anti-K b) antibodies.

Statistical Analysis. Results are presented as the mean ± SD. Student's t test was used for comparison between the control and knockout mouse groups. For individual comparisons between two measurements, the paired t test was used. The level of significance was preset at P <0.05.

Results

Increased Plasma Iron and TS in β2m-/- Mice. Under normal circumstances, the vast majority of plasma iron is bound to transferrin. Transferrin-bound iron is transported to various sites of utilization, where it is delivered to cells via transferrin receptors (24). In HH homozygotes, the earliest laboratory abnormalities are elevated plasma iron concentrations and increased TS (25, 26). Therefore, we measured plasma iron and TIBC, and calculated transferrin saturation from that in 2- and 12-mo-old mice. At both ages, β2m-/- mice had persistently higher plasma iron concentrations (Fig. 1 A) and TS (Fig. 1 B) than either B6 or CD8-/- control mice.

1976 Iron Metabolism in β2m-/- Mice
### Increased Iron Concentrations in Livers from β2m⁻/⁻ Mice

Diagnosis of iron storage disease normally requires a biopsy of the liver, the major organ for excess iron storage (1). Further quantitative determination of the hepatic iron concentration, histochemical visualization of the cellular distribution of iron, and pathological examination of the extent of injury provide essential information about the type and degree of iron loading.

Confirming the finding reported earlier (11, 13), 8-wk-old β2m⁻/⁻ mice had hepatic iron concentrations that were more than twice as high as in B6 control mice. In contrast, iron concentration in the livers of CD8⁻/⁻ mice
Figure 2. Storage of excess iron in hepatic cells of mice fed with different diets (Prussian blue staining). (A and B) Light micrograph of a liver section from B6 (indicated as β2m+/+, A) and β2m−/− (B) mouse aged 2 mo and fed with a standard diet. In the liver of the β2m−/− mouse, liver parenchymal cells with an increased iron content are visible around portal spaces. (C and D) Light micrograph of a liver section from B6 (indicated as β2m+/+, C) and β2m−/− (D) mouse aged 2 mo at the start of the experiment and fed with an iron-enriched diet (2.5% wt/wt carbonyl iron) for 2 wk. Beside parenchymal cells, heavily iron-loaded Kupffer cells are visible in the β2m−/+ liver. Kupffer cells are indicated with arrows. Original magnification ×300.

Erythroid Parameters. Excess storage iron can occur in a large group of hematological diseases, collectively termed iron-loading anemias, in which ineffective erythropoiesis or abnormalities of hemoglobin synthesis are prominent (1). They are characterized by anemia and a subsequent increase in iron absorption. Ultimately, the inefficient use of the iron leads to iron overload. To rule out the possibility that anemia could account for the abnormal iron storage defect demonstrated in β2m−/− mice, we determined several erythroid parameters. The results demonstrated that RBC counts, Hb, HCT, and MCV values were even
higher in the β2m−/− mice than in the other animal groups (Table 1). Thus, the excess storage iron found in β2m−/− mice could not be related to defective erythropoiesis or Hb synthesis.

Failure to Regulate Iron Absorption in β2m−/− Mice. One of the hallmarks of iron homeostasis is its exclusive regulation at the sites of absorption (28, 29). The capacity to reduce or increase absorption of iron in response to increased or reduced iron stores is well documented. In HH, patients fail to decrease their iron absorption despite the accumulation of iron in the body (30–32).

Iron retention, here defined as the percentage of 59Fe found in the body 7 d after the administration of an oral radioactive test dose, was plotted against iron concentration in livers (Fig. 4 A). Despite the fact that β2m−/− mice have increased amounts of iron in livers when fed a standard diet, they did not downregulate their IR as compared to control B6 mice that were fed the same standard diet. Importantly, B6 mice that were fed an iron-enriched diet promptly downregulated IR as a response to the modest increase of iron in their livers.

To test whether β2m−/− mice can downregulate iron absorption as a response to a similar overload induced by diet, iron retention was measured before and after feeding the animals with an iron-enriched diet for 14 d. Again, the downregulation of IR in response to moderately increased iron stores could readily be demonstrated in B6 and CD8−/− mice. In marked contrast to the results observed in these
Table 1.   Erythroid Parameters

<table>
<thead>
<tr>
<th>Mice</th>
<th>Age (mo)</th>
<th>n</th>
<th>RBC (10^12/liter)</th>
<th>Hb (mmol/liter)</th>
<th>HCT (%)</th>
<th>MCV (fl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B6</td>
<td>2</td>
<td>19</td>
<td>9.4 ± 0.3</td>
<td>8.9 ± 0.3</td>
<td>45 ± 1</td>
<td>48 ± 1</td>
</tr>
<tr>
<td>B6</td>
<td>12</td>
<td>6</td>
<td>8.7 ± 0.5</td>
<td>7.9 ± 0.5</td>
<td>40 ± 2</td>
<td>45 ± 1</td>
</tr>
<tr>
<td>β2m⁻⁻⁻⁻</td>
<td>2</td>
<td>11</td>
<td>10.0 ± 0.4</td>
<td>10.2 ± 0.5</td>
<td>53 ± 2</td>
<td>53 ± 1</td>
</tr>
<tr>
<td>β2m⁻⁻⁻⁻</td>
<td>12</td>
<td>6</td>
<td>10.4 ± 0.3</td>
<td>10.2 ± 0.3</td>
<td>51 ± 1</td>
<td>49 ± 2</td>
</tr>
<tr>
<td>CD8⁻⁻⁻⁻</td>
<td>2</td>
<td>13</td>
<td>9.0 ± 0.3</td>
<td>8.6 ± 0.3</td>
<td>44 ± 1</td>
<td>49 ± 2</td>
</tr>
<tr>
<td>CD8⁻⁻⁻⁻</td>
<td>12</td>
<td>6</td>
<td>8.7 ± 0.7</td>
<td>8.0 ± 0.5</td>
<td>40 ± 1</td>
<td>46 ± 1</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD. n, number of animals.

mice, β2m⁻⁻⁻⁻ mice, even when challenged with high dietary iron, were unable to reduce their iron retention (Fig. 4 B).

A more specific indicator of the regulation of iron absorption is the so-called MT, here defined as the ratio of the iron ultimately retained in the body vs. the iron initially taken up by the gut mucosa. This is believed to be the critical step that is defective in HH patients (33). We used a double-isotope technique (32; Santos, M., K.J.H. Wienk, M.W. Schilham, H. Clevers, M. DeSouza, and J.J.M. Marx, manuscript in preparation) to discriminate between initial MU and subsequent iron retention, and hence calculate MT of iron. The MT in β2m⁻⁻⁻⁻ mice that were maintained on a standard diet was consistently higher than MT in normal or CD8⁻⁻⁻⁻ mice (Table 2). After experimental iron overload, MT in B6 and CD8⁻⁻⁻⁻ mice was strongly reduced, whereas MT in β2m⁻⁻⁻⁻ mice was only mildly decreased (Fig. 4 C).

Taken together, the capacity of β2m⁻⁻⁻⁻ mice to regulate iron absorption in response to changes in iron stores was strikingly affected at the level of the MT of iron to the plasma.

Fetal Liver Cell Transfer. As an alternative site for the primary iron handling defect in HH patients, the reticuloendothelial (RE) system has been proposed. Specifically, it has been shown that the RE cells in HH patients are impaired in their capacity to store iron (34-36). A possible implication of these studies is that an abnormality in RE iron metabolism might affect the control of iron absorption by the intestinal mucosa (37). We attempted to address this issue by reconstituting lethally irradiated B2m⁻⁻⁻⁻ mice with hematopoietic cells from normal mice. It was expected that if RE cells play a role in regulating iron absorption, β2m⁻⁻⁻⁻-reconstituted mice should be able to correct their abnormalities in iron homeostasis. All β2m⁻⁻⁻⁻ mice reconstituted with β2m⁻⁻⁻⁻-derived cells had stainable iron in parenchymal cells, and they were indistinguishable from untreated β2m⁻⁻⁻⁻ mice (Figs. 2 B and 5, A and C). No stainable iron was detected in B6-reconstituted B6 mice (not shown). All attempts to reconstitute B6 mice with β2m⁻⁻⁻⁻ fetal liver cells failed, most likely because of rejection of the transplanted hematopoietic cells by host NK cells (38). A striking change in hepatocellular iron distribu-
Table 2. Increased Intestinal MT in β2m−/− Mice

<table>
<thead>
<tr>
<th>Age (mo)</th>
<th>B6 n</th>
<th>MT ± SD</th>
<th>CD8−/− n</th>
<th>MT ± SD</th>
<th>β2m−/− n</th>
<th>MT ± SD</th>
<th>P vs. B6</th>
<th>P vs. CD8−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>12</td>
<td>0.74 ± 0.06</td>
<td>6</td>
<td>0.72 ± 0.06</td>
<td>6</td>
<td>0.89 ± 0.04</td>
<td>&lt;0.0001</td>
<td>&lt;0.0005</td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>0.74 ± 0.04</td>
<td>5</td>
<td>0.64 ± 0.04</td>
<td>7</td>
<td>0.86 ± 0.05</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>0.70 ± 0.04</td>
<td>6</td>
<td>0.72 ± 0.05</td>
<td>6</td>
<td>0.82 ± 0.05</td>
<td>&lt;0.0001</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>12</td>
<td>6</td>
<td>0.64 ± 0.05</td>
<td>6</td>
<td>0.65 ± 0.05</td>
<td>6</td>
<td>0.86 ± 0.06</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

MT was determined as the ratio of IR/MU. Each mouse received orally a double isotope test dose containing 59Fe and 51Cr. MU was calculated 1 d later. 59Fe retention was determined by whole-body counting 7 d after administration of the test dose. Data are presented as mean ± SD. n = number of animals; P = Student’s t test for comparison of β2m−/− mice with B6 control and CD8−/− mice.

Figure 5. Liver iron in radiation chimeras (Prussian blue staining). All animals were 6 wk old at the start of the experiment. (A and C) Liver sections from β2m−/− mice 1 mo (A) and 3 mo (C) after reconstitution with fetal liver cells from β2m−/− donor mice. (B and D) Liver sections from β2m−/− mice 1 mo (B) and 3 mo (D) after reconstitution with fetal liver cells from B6 donor mice. Heavily iron-loaded Kupffer cells (arrow) are visible 1 mo after reconstitution. After 3 mo, no iron depositions are present. Original magnification ×300.
monstrable iron in macrophages in HH is minimal until the patients and contrasts with the histopathological findings in other iron storage disorders in man. The amount of defective in HH patients (33). Under increased iron load-

Discussion

Previously, we have reported the existence of hepatic iron overload in β2m-/- mice similar to that found in HH (11). This was based on a histological and quantitative studies of the steady-state iron distribution and content in tissues of β2m-/- mice. These results were confirmed more recently by others (13).

Now we report a detailed analysis of the nature of the iron metabolism defect of β2m-/- mice. These mice recapitulate all central features of HH; i.e., increased TS, visible iron depositions, specifically in parenchymal cells of the liver, and a dysregulation of intestinal iron absorption. The defect appears to be caused by the lack of a class I-like, β2m-dependent molecule, and not by the lack of CD8+ T cells or TAP-dependent MHC molecules. Moreover, although the storage abnormalities in the liver of β2m-/- mice can be compensated by cell transfer, the increased intestinal iron absorption is not reduced by substitution of the hematopoietic compartment.

Intestinal Iron Absorption. The capacity of β2m-/- mice to regulate intestinal iron absorption in the face of increased iron stores seems to be manifestly impaired. Similarly, in HH, patients fail to decrease their iron absorption despite the accumulation of iron in the body (30-32).

Iron retention is only the ultimate result of the iron absorption process, which can be divided into two steps: MU from the intestinal lumen and the subsequent transfer of iron through mucosal cells into the blood. Under normal conditions, not all the iron is transferred into the circulation, but remains inside the mucosal cell and is rapidly lost after desquamation of the epithelial cells. MU is influenced by many intraluminal factors: the state of iron in the test dose (ferric or ferrous, heme or nonheme), the amount of iron, the composition of the test dose, gastric and intestinal secretions, and the state of the brush border of the mucosal cells. The next step, MT, is less dependent on these intraluminal factors and will better reflect the iron status of the body. In β2m-/- mice, MT of iron into the plasma is increased iron overload in β2m-/- mice similar to that found in HH (47-51). In these studies, excess dietary iron alone failed to produce the typical parenchymal iron accumulation and the resulting organ damage, even when iron concentrations in the liver were three to four times higher than the critical iron level associated with fibrosis in HH (52). In accordance with these findings, we observed heavily iron-loaded macrophages in livers from control B6 mice after dietary manipulation. Apparently, surplus iron is redistributed from parenchymal cells to the mononuclear phagocyte system in liver of dietary iron-loaded animals (53). This notion is consistent with previous studies that show a decreased iron storage capacity of macrophages in HH (35, 36, 54). Similarly, it would appear that the Kupffer cells of β2m-/- mice fail to store excess iron, even when surrounded by iron-loaded parenchymal cells. The apparent redistribution of stored iron from parenchymal to Kupffer cells upon transfer of hematopoietic cells might suggest that β2m-/- Kupffer cells, like HH macrophages, carry an intrinsic defect in iron storage.

Molecular Nature of the Defect. β2m is required for the normal surface expression of classical and nonclassical MHC class I molecules (14, 15). Thus, mice lacking a functional β2m gene fail to express MHC class I products (16, 17), and consequently they lack CD8+ lymphocytes.

The TAP-1 and TAP-2 proteins are required for transport of cytosolic peptides into the endoplasmic reticulum for association with classical class I molecules (55-57). TAP-1 mutant mice are defective in peptide transport, and consequently do not express classical class I molecules on the surface of their cells (18). Recently, it was shown that some nonclassical MHC I molecules may be expressed independently of TAP function (19, 20). Livers from TAP1-/- mice had normal iron concentration values, implying that classical MHC class I molecules are not responsible for the observed iron storage phenotype in β2m-/- mice. Rather, it would appear that a "nonclassical," β2m-associated molecule performs a function in iron metabolism. Such a molecule would be dependent on the presence of β2m, but independent of TAP function.

The gene responsible for HH has been located on the short arm of chromosome 6, in linkage disequilibrium with the HLA-A locus (8, 58), where several nonclassical MHC-I genes have been identified (59-61). While this paper was under submission, a novel MHC class I-like gene, termed HLA-H, was reported to be mutated in a large majority of HH patients (62). Two missense variants were found in 87% of HH patients. Importantly, the most preva-
lent mutation was inferred to disrupt the putative β2m-binding site on the HLA-H molecule. The current data lend independent, functional support for a causative role of HLA-H mutations in HH.

**Iron Homeostasis.** One of the hallmarks of iron homeostasis is its exclusive regulation at the sites of absorption (28, 29). It is not clear yet what mechanism regulates iron absorption from the gut, but two main hypotheses have been suggested from observations made in HH patients. One assumes a generalized defect in iron storage in the RE and in the feedback regulation of iron absorption (37). The other hypothesis assumes a direct role of the intestinal mucosal cells in regulating iron absorption (63-68).

Our results in the reconstituted β2m−/− mice support the view that the primary iron metabolism defect is expressed both at the level of the gut epithelium and of Kupffer cells in the liver. The histopathological analysis indicated that the liver iron storage pattern was normalized, indicating the involvement of hematopoietic-derived cells, Kupffer cells or others, in the regulation of cellular iron storage in the liver. However, the iron absorption defect of the mucosal intestinal cells could not be corrected by the transferred cells. The defect appears not to reside in the liver parenchyma. Consistent with this view is the observation that inadvertently transplanted livers from HH patients into recipients with otherwise normal iron metabolism returned to normal iron concentrations (69-71). In these documented cases, a diseased liver was transplanted into recipients with normal hematopoietic compartment and gut mucosa. We propose that HLA-H is responsible for both primary metabolic defects in HH, namely the pattern of iron accumulation in the liver and the failure to regulate iron absorption.

We thank Drs. S. Tonegawa and C. Levelt for the livers from TAP1−/− mice, Drs. F. Arosa and G. Porto for valuable discussions, and Dr. Els Ahsman for her contribution to histology studies.

This work was funded by a grant from Junta Nacional de Investigación Científica e Tecnológica - PRAXIS XXI (BD/2866/94).

Address correspondence to Manuela Santos, Department of Immunology, University Hospital Utrecht, Room F03.821, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. The current address for Marco W. Schilham is Department of Pediatrics, University Hospital, PO Box 9600, 2300 RC Leiden, The Netherlands.

Received for publication 10 July 1996 and in revised form 26 August 1996.

**References**


